Department of Pediatric Dentistry, Medical University of Lodz, Lodz, Poland.
Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University of Lodz, Lodz, Poland.
Cancer Res Treat. 2021 Jan;53(1):252-260. doi: 10.4143/crt.2020.275. Epub 2020 Aug 24.
The study aimed to assess the differences in dental maturation between childhood cancer survivors and healthy children.
Fifty-nine cancer patients including 16 (27.1%) girls and 43 (72.8%) boys, aged between 4 and 16 years, underwent dental and radiographic examinations. The mean duration of anticancer therapy was 16.8 months (range, 1 to 47 months), and 4.6 years (range, 8 to 123 months) had passed since the termination of disease. The control group consisted of 177 panoramic radiographs of age- and sex-matched healthy individuals. Dental age (DA) was estimated with Demirjian's scale and delta age, i.e., DA-chronological age (CA), was used to compare groups.
The DA of cancer survivors was accelerated by almost 1 year compared to their CA (9.9±3.1 vs. 8.9±2.8, p=0.040). The greatest difference was observed among patients with brain tumor: delta (DA-CA) was 2.2±1.1 years. Among all cancer patients, only children with familial adenomatous polyposis (FAP)-associated hepatoblastoma (HP) demonstrated delayed DA, with regard to both other cancer survivors (p=0.011) and healthy patients (p=0.037). All four patients with HP suffered from FAP, and three of them had documented adenomatous polyposis coli (APC) genes mutation. The DA of cancer patients having teeth with short roots was significantly greater than that of the cancer survivors without this anomaly (12.8±3.2 vs. 9.0±2.4, p < 0.001).
DA in children may be altered by cancer disease.
本研究旨在评估儿童癌症幸存者与健康儿童之间的牙齿成熟度差异。
59 名癌症患者，包括 16 名（27.1%）女孩和 43 名（72.8%）男孩，年龄在 4 至 16 岁之间，接受了牙科和放射学检查。抗癌治疗的平均持续时间为 16.8 个月（范围为 1 至 47 个月），自疾病结束以来已经过去了 4.6 年（范围为 8 至 123 个月）。对照组由 177 名年龄和性别匹配的健康个体的全景片组成。使用 Demirjian 量表估计牙龄（DA），并使用 DA-年龄（CA）差值来比较组间差异。
与 CA 相比，癌症幸存者的 DA 加速了近 1 年（9.9±3.1 与 8.9±2.8，p=0.040）。在脑瘤患者中观察到的差异最大：差值（DA-CA）为 2.2±1.1 年。在所有癌症患者中，只有家族性腺瘤性息肉病（FAP）相关肝母细胞瘤（HP）患者的 DA 延迟，与其他癌症幸存者（p=0.011）和健康患者（p=0.037）相比均如此。所有 4 名 HP 患者均患有 FAP，其中 3 名患者存在 APC 基因突变。患有短根牙的癌症患者的 DA 明显大于无此异常的癌症幸存者（12.8±3.2 与 9.0±2.4，p<0.001）。
癌症疾病可能会改变儿童的 DA。
